Alzheimer’s disease blood tests? Bringing plasma biomarkers into clinical practice

Blood biomarkers are taking off in the Alzheimer’s disease field, showing promise for diagnosis, prognostication, and treatment monitoring. Current diagnostic…

Date: 6th September 2022

Immunotherapy for Alzheimer’s disease: targeting β-amyloid and tau

The complexity of Alzheimer’s disease (AD) pathogenesis has led to difficulties understanding the disease and, therefore, impacted the development of…

Date: 29th July 2022

Alzheimer’s disease blood tests? Bringing plasma biomarkers into clinical practice

Blood biomarkers are taking off in the Alzheimer’s disease field, showing promise for diagnosis, prognostication, and treatment monitoring. Current diagnostic…

Date: 6th September 2022

Immunotherapy for Alzheimer’s disease: targeting β-amyloid and tau

The complexity of Alzheimer’s disease (AD) pathogenesis has led to difficulties understanding the disease and, therefore, impacted the development of…

Date: 29th July 2022

Synaptic function in Alzheimer’s disease

Alzheimer’s disease (AD) is a neurodegenerative disorder predominately afflicting the older population – and with recent exponential developments in medicine…

Date: 15th June 2022

Novel developments in biomarkers for FTD

Frontotemporal dementia (FTD) occurs when nerve cells in the frontal and temporal lobes of the brain are lost, causing the…

Date: 7th April 2022

Therapeutic plasma exchange to slow cognitive decline in Alzheimer’s disease

Therapeutic plasma exchange (TPE) is used to treat a variety of neurological, immunological, and metabolic disorders. The procedure removes patient…

Date: 3rd February 2022

Recent advances in plasma biomarkers for Alzheimer’s disease

In recent years, blood-based biomarkers have taken off in the dementia space, representing a less invasive, more cost-effective, and accessible…

Date: 2nd February 2022